Celestra
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Celestra develops technology to detect cancer and other diseases at an early stage by analysing blood samples, looking for circulating tumour cells and fragments of cell-free DNA, and by processing large-scale genomic data.
Its services and tools are aimed at clinical and diagnostic applications in cancer detection and monitoring. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company organises its work across four areas: genome-based healthcare, a liquid-biopsy platform, cancer diagnosis and monitoring, and early cancer detection. It operates its own biological big-data centre to accumulate and commercialise large volumes of biomedical data.
Summary is AI-generated and may contain errors · figures from DART filings
Celestra in five facts
What does Celestra do?
Celestra develops technology to detect cancer and other diseases at an early stage by analysing blood samples, looking for circulating tumour cells and fragments of cell-free DNA, and by processing large-scale genomic data.
Where is Celestra listed and in which sector?
Celestra (Korean name: 셀레스트라) trades under KRX code 352770 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Celestra?
Its market capitalisation was US$10.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Celestra's latest annual revenue and operating profit?
For fiscal year 2025, Celestra reported revenue of US$1.5M, an operating loss of US$5.9M and a net loss of US$8.9M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 76.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.